Related Experiment Video
Updated: Jul 15, 2026
14:34
A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
Published on: April 3, 2026
PLK1 inhibitors: setting the mitotic death trap
Simon Plyte1, Andrea Musacchio
1Congenia S.r.l., Genextra Group, Via Adamello 16, I-20139 Milan, Italy. simon.plyte@congenia.it
Current Biology : CB
|April 18, 2007
Summary
BI 2536 is a novel inhibitor of Polo-like kinase 1 (Plk1), a key regulator of cell division. This study explores its anti-tumor effects, linking chemical inhibition to potential therapeutic applications in cancer treatment.
Area of Science:
- Cell Biology
- Molecular Biology
- Pharmacology
Background:
- Polo-like kinase 1 (Plk1) is crucial for mitotic progression in eukaryotes.
- Plk1 is implicated in the transformation of human cells, suggesting its role in cancer development.
- Targeting Plk1 offers a potential strategy for anti-cancer therapies.
Purpose of the Study:
- To investigate the cytological activities of the Plk1 inhibitor BI 2536.
- To evaluate the anti-tumor efficacy of BI 2536.
- To establish a connection between chemical inhibition of Plk1 and its therapeutic potential.
Main Methods:
- Administration of BI 2536, a selective Plk1 inhibitor.
- Cytological analysis to observe effects on cell division.
- Assessment of anti-tumor activity in relevant models.
Main Results:
- BI 2536 demonstrates significant Plk1 inhibitory activity.
- Cytological studies reveal Plk1 inhibition disrupts mitotic progression.
- BI 2536 exhibits notable anti-tumor effects.
Conclusions:
- BI 2536 is a potent and selective inhibitor of Plk1.
- Plk1 inhibition by BI 2536 has anti-cancer implications.
- The study bridges chemical biology with potential clinical applications for Plk1-targeted cancer therapy.
More Related Videos
Related Concept Videos
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
01:10Drugs that Destabilize Microtubules
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
01:23Negative Regulator Molecules
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
01:15Drugs that Stabilize Microtubules
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
02:15M-Cdk Drives Transition Into Mitosis
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...